Sector News

Smith & Nephew shares jump 10pc on Stryker bid reports

December 26, 2014
Life sciences
Shares in Smith & Nephew spiked by almost 10pc on Wednesday following reports that its US rival Stryker is planning a £13bn takeover bid.
 
Stryker, which makes surgical implants, is looking at offering a 30pc premium to Smith & Nephew’s share price, which rose to £11.80 on Wednesday morning, valuing the company at around £10.6bn. THe stock closed up 7.7pc at £11.73 on Wednesday.
 
An approach could be made within weeks, Bloomberg reported.
 
In May, Stryker boss Kevin Lobo admitted that he was in the early stages of considering an acquisition of Smith & Nephew but was not prepared to make an immediate bid. The statement put Stryker in a “cooling-off” period that prevented it from approaching the FTSE 100 company until November.
 
Stryker has held discussions on financing the deal, and already considered the competition issues of a tie-up, according to Bloomberg citing unnamed sources.
 
The UK’s takeover rules state that when a potential bidder is in a cool-off period it can still actively consider an offer but it is banned from “taking any steps in connection with a possible offer for the [target] company where knowledge of the possible offer might be extended outside those who need to know in the potential offeror and its immediate advisers”. As a result, it is widely accepted that talks must be kept to only dedicated advisers in order to keep leaks to a minimum.
 
The Michigan-based company is reportedly not weighing a so-called inversion deal – an acquisition which involves a US company moving its headquarters outside the country to escape high corporation tax rates at home.
 
While inversions surged in popularity in the early part of this year, a US Treasury clampdown in September scuppered a number of high profile deals, including AbbVie’s abandoned tie-up with Shire, and stopped other potential deals in their tracks.
 
Analysts are divided over the strategic logic of a Stryker and Smith & Nephew tie-up. Morgan Stanley analysts noted that a merger would slow the US company’s annual growth, which currently stands at around 5pc compared with Smith & Nephew’s 3pc.
 
Analysts at Bernstein have, however, put the chances of a merger at more than a third, saying a tie-up could help cut costs at a time when the industry is facing intense pricing pressure. They also said Stryker could be keen for a merger to help it compete with the scale of the combined Zimmer and Biomet, two major US medical technology companies who announced plans to merge earlier this year.
 
By Andrew Trotman, Denise Roland and Ashley Armstrong
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”